Press Archive
Chiara Manzini, Ph.D., assistant professor in pharmacology & physiology, published research in the American Journal of Human Genetics about a newly discovered mutation in the INPP5K gene, which leads to short stature, muscle weakness, intellectual disability, and cataracts,…
The School of Medicine and Health Sciences values and supports all members of our diverse community and the contributions they make to our mission.
A large international survey, published in the Journal of the European Academy of Dermatology & Venereology by researchers from La Roche-Posay and GW, asked nearly 20,000 participants about their sun protection behavior and skin cancer awareness.
The Rheumatology Research Foundation recently awarded Aileen Y. Chang, M.D., M.S.P.H., a $75,000 pilot grant to fund her research in rheumatology for a project entitled, “A Pilot Study of the Pathogenesis of Chikungunya Arthritis in the Americas.”
Jeffrey M. Bethony, Ph.D., professor, and David Diemert, M.D., associate professor, both in the Department of Microbiology, Immunology, and Tropical Medicine, served as co-authors on a review on hookworm infection published in Nature Reviews: Disease Primers.
The GW School of Medicine and Health Sciences welcomes Sara Melita, who will serve as the senior advisor and chief of staff to Jeffrey S. Akman, M.D., vice president for health affairs at GW, Walter A. Bloedorn Professor of Administrative Medicine, and dean of the GW School of Medicine and…
Patricia Berg, Ph.D., professor of biochemistry and molecular medicine, has been named a Fellow of the American Association for the Advancement of Science.
GW formally launched the GW Cancer Center with a ribbon-cutting and grand opening celebration the evening of Wednesday, Dec. 7.
Matthew Colonnese, Ph.D., assistant professor of pharmacology and physiology, published a paper in the Journal of Neuroscience establishing a mouse model for human fetal electrographic development.
Narine Sarvazyan, Ph.D., professor of pharmacology and physiology, parntered with Noctural Product Development to receive a $2.27 million Phase II STTR grant to support ongoing efforts to design, produce, and test real-time lesion visualization tools for cardiac ablation procedures.